by Kyle | Jul 11, 2022 | News
The biotech firm AXIM Biotechnologies Inc. AXIM reports that it has developed fast, point-of-care tests to help eye doctors detect dry eye syndrome, a big issue in today’s world. It is important to differentiate from simple allergies for proper care and treatment. Up...
by Kyle | May 24, 2022 | Press Release
SAN DIEGO, May 24, 2022 (GLOBE NEWSWIRE) — AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular surface diseases announced today that its scientific team has completed...
by Kyle | May 10, 2022 | Press Release
SAN DIEGO, May 10, 2022 (GLOBE NEWSWIRE) — AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting dry eye disease (DED), today announced that it has developed a novel tear sample...
by Kyle | Apr 27, 2022 | Press Release
SAN DIEGO, April 27, 2022 (GLOBE NEWSWIRE) — AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting Dry Eye Disease (DED), announced today that it has successfully developed a...
by Kyle | Apr 19, 2022 | Press Release
Summary: AXIM places strategic focus on commercializing FDA-cleared Dry Eye Disease (DED) diagnostic system Plans to address largely underserved DED diagnosis market with patent pending tear collection method and approved tests, supported by world-class DED...
